Randomized Feasibility Study to Determine the Feasibility of Neurotization of the Nipple Areolar Complex at the Time of Nipple Sparing Mastectomy and Prosthetic Based Reconstruction

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This phase II trial tests the willingness of patients undergoing nipple sparing mastectomy (NSM) to enroll in a randomized study of NSM with or without neurotization of the nipple areolar complex (NAC). This trial also compares patient reported outcomes, including quality of life and breast and NAC sexual functionality, for patients undergoing NSM with or without neurotization of the NAC. NSM is a standard practice option for patients undergoing preventative mastectomy, but many report dissatisfaction with decreased nipple sensation. Neurotization is a surgical technique using a nerve graft in an attempt to restore NAC sensation. Neurotization during NSM and reconstruction may restore NAC sensation and improve quality of life in breast cancer patients.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Female patients age \>= 18

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

• Planned nipple sparing mastectomy (NSM)

• Ideal NSM candidates would meet the following criteria:

‣ Cup size A-C

⁃ BMI \<34

⁃ Ptosis grade \< 2

⁃ Clinical stage 0 - T2N0

⁃ Final planned implant volume \< 400cc

⁃ Inframammary or lateral mammary incision

⁃ Tumor \> 0.5cm from the nipple areolar complex (NAC)

⁃ No prior breast reduction, mastopexy, or periareolar incisions on side of planned NSM

⁃ No prior breast radiation on side of planned NSM

⁃ Tumor \<0.5cm from NAC (including suspicious calcifications or MRI enhancement)

⁃ No planned post mastectomy radiation (PMRT)

⁃ No nicotine use within 4 weeks of surgical date

Locations
United States
Florida
Mayo Clinic in Florida
RECRUITING
Jacksonville
Contact Information
Primary
Clinical Trials Referral Office
mayocliniccancerstudies@mayo.edu
855-776-0015
Time Frame
Start Date: 2023-12-05
Estimated Completion Date: 2026-11-10
Participants
Target number of participants: 14
Treatments
Active_comparator: ARM I (control)
Patients undergo standard of care NSM on study.
Experimental: ARM II (neurotization)
Patients undergo neurotization during standard of care NSM on study.
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic

This content was sourced from clinicaltrials.gov